MJardin Group, Inc. (MJARF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.62: the stock has moved about 38% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMJardin Group, Inc. (MJARF) trades at $0.0001. MJardin Group, Inc. cultivates, processes, and sells cannabis products in Canada and the United States. The company also provides consulting services to licensed cannabis operators. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for MJARF: MJARF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
MJardin Group, Inc. (MJARF) Healthcare & Pipeline Overview
MJardin Group, Inc. operates within the cannabis industry, providing cultivation, processing, and retail services, along with consulting for licensed cannabis operators, primarily in Canada and the United States. The company manages a portfolio of cannabis operations, navigating a competitive and evolving regulatory landscape.
What Is the Investment Thesis for MJARF?
MJardin Group operates in the evolving cannabis industry, presenting both opportunities and risks. With a negative P/E ratio of -0.00 and a profit margin of -304.6%, the company's financial performance requires careful consideration. A gross margin of 49.7% indicates potential in its core operations. Growth catalysts include expansion into new markets and increased operational efficiency. However, investors should be aware of the risks associated with regulatory changes and competition within the cannabis sector. The company's beta of 0.62 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
MJARF Key Highlights
Gross Margin of 49.7% indicates potential profitability in core cannabis operations.
- Operates or advises on 32 cannabis operations, reflecting a broad industry presence.
- Provides consulting services, diversifying revenue streams beyond direct cannabis sales.
- Beta of 0.62 suggests lower volatility compared to the overall market.
- Founded in 2014, indicating a relatively young company in a rapidly evolving industry.
Who Are MJARF's Competitors?
MJARF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MJARF's Key Strengths?
Diversified revenue streams through cultivation, processing, and consulting.
- Portfolio of managed or advised cannabis operations.
- Expertise in navigating the complex cannabis regulatory landscape.
- Established presence in both Canada and the United States.
What Are MJARF's Weaknesses?
Negative profitability and high operating expenses.
- Dependence on evolving cannabis regulations.
- Intense competition in the cannabis industry.
- Limited brand recognition compared to larger competitors.
What Are the Key Risks for MJARF?
Financial-distress signal — its Altman Z-Score of -8.28 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Changes in cannabis regulations could negatively impact MJardin's operations and profitability.
- Intense competition in the cannabis industry could put pressure on MJardin's market share and margins.
- Fluctuations in cannabis prices could impact MJardin's revenue and profitability.
- Negative public perception of cannabis could limit demand for MJardin's products.
What Are MJARF's Competitive Advantages?
- Operational Expertise: MJardin has developed expertise in cannabis cultivation, processing, and retail operations.
- Consulting Services: The company's consulting services provide a competitive advantage by offering specialized knowledge to cannabis operators.
- Portfolio of Operations: MJardin's portfolio of managed or advised cannabis operations provides a diversified revenue stream.
What Does MJARF Do?
Founded in 2014 and headquartered in Ontario, Canada, MJardin Group, Inc. operates as a multifaceted cannabis company. Through its subsidiaries, MJardin cultivates, harvests, processes, and sells cannabis products in both Canada and the United States. Beyond direct cannabis production and sales, the company offers a suite of consulting services tailored to licensed cannabis operators. These services encompass strategic capital and financing solutions, project management for cultivation facilities, assistance with securing licenses, facility design expertise, systems implementation support, facility and equipment leasing options, construction oversight, and facility ramp-up assistance. MJardin also provides access to its intellectual property to help licensed cannabis operators optimize their cultivation and retail businesses. The company owns, manages, or advises on a portfolio of 32 cannabis operations, demonstrating its broad involvement in the cannabis industry value chain.
What Products and Services Does MJARF Offer?
- Cultivates cannabis plants in Canada and the United States.
- Harvests cannabis crops for processing.
- Processes cannabis into various products.
- Sells cannabis products through retail channels.
- Provides strategic capital and financing to cannabis operators.
- Offers project management services for cannabis cultivation facilities.
- Assists with securing licenses for cannabis operations.
- Provides facility design and systems implementation support.
How Does MJARF Make Money?
- Cultivation and Sale of Cannabis: MJardin generates revenue through the cultivation, processing, and sale of cannabis products.
- Consulting Services: The company provides consulting services to licensed cannabis operators, generating revenue through fees for these services.
- Facility and Equipment Leasing: MJardin leases facilities and equipment to cannabis operators, generating revenue through lease payments.
What Industry Does MJARF Operate In?
MJardin Group operates within the rapidly evolving cannabis industry, which is characterized by changing regulations, increasing competition, and growing consumer demand. The industry is experiencing significant growth, driven by the legalization of cannabis in various jurisdictions. MJardin competes with other cannabis producers and retailers, as well as companies providing consulting services to the industry. Key competitors include ALID (Allied Corp), APPB (AppTech Payments Corp), CBDY (CBD of Denver, Inc.), CNNA (CANNA-Global Acquisition Corp), and CPMD (Compass Diversified Holdings). The company's success depends on its ability to navigate the regulatory landscape, differentiate its products and services, and efficiently manage its operations.
Who Are MJARF's Key Customers?
- Licensed Cannabis Operators: MJardin provides consulting services and leases facilities/equipment to licensed cannabis operators.
- Retail Consumers: The company sells cannabis products directly to retail consumers in jurisdictions where it is legal.
- Wholesale Distributors: MJardin may sell cannabis products to wholesale distributors for further distribution.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
MJardin Group, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Ali Mahdavi. MJARF has traded publicly since 2018.
Earnings Track Record
MJardin Group, Inc. has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 456.9% below estimates on average.
Financial Health
MJardin Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.28 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for MJardin Group, Inc. stands at 48.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.6%, showing how much profit it generates from its asset base. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
Forward Outlook
Wall Street analysts project MJardin Group, Inc. revenue of about $38.0M for fiscal 2026, with EPS near $-0.10.
MJARF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MJARF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
MJARF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MJARF.
Price Targets
Wall Street price target analysis for MJARF.
MJARF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MJARF; grades run from A+ (80-100) to F (below 30).
Leadership: Ali Mahdavi
CEO
Ali Mahdavi serves as the CEO of MJardin Group, bringing extensive experience in the cannabis industry. His background includes a strong focus on strategic development and operational excellence within highly regulated markets. He has a proven track record of driving growth and innovation in the cannabis sector. Prior to joining MJardin, Mahdavi held leadership positions in various cannabis companies, where he oversaw cultivation, processing, and retail operations. His expertise also encompasses regulatory compliance and market expansion strategies.
Track Record: Under Ali Mahdavi's leadership, MJardin Group has focused on optimizing its operations and expanding its consulting services. Key achievements include streamlining cultivation processes and enhancing the company's portfolio of managed cannabis operations. Mahdavi has also prioritized building strong relationships with regulatory bodies and industry partners. His strategic decisions have aimed at positioning MJardin for long-term growth and sustainability in the evolving cannabis market.
MJARF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MJardin Group, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be experiencing financial distress, or be newly formed. Investing in OTC Other stocks carries significant risks due to the potential for fraud, lack of transparency, and limited regulatory oversight compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's true financial health.
- Low Liquidity: Limited trading volume can lead to price volatility and difficulty in buying or selling shares.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- Going Concern Risk: Companies on the OTC Other tier may be facing financial difficulties, raising concerns about their ability to continue operating.
- Information Asymmetry: The limited availability of information can create an uneven playing field for investors.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established Business Operations: Assess the length of time the company has been in operation and its track record.
- Industry Partnerships: Look for partnerships with reputable companies in the cannabis industry.
- Regulatory Compliance: Verify that the company is compliant with relevant cannabis regulations.
- Positive News Coverage: Check for positive news articles or press releases about the company.
- Active Investor Relations: Evaluate the company's communication with investors and its responsiveness to inquiries.
Common Questions About MJARF (Healthcare)
What do analysts say about MJARF stock?
As of 2026-03-16, formal analyst ratings for MJARF are limited due to its OTC listing and smaller market capitalization. Investors should focus on fundamental analysis, monitoring revenue growth, gross margins, and cash flow.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be less reliable than exchange-listed data.
- The cannabis industry is subject to rapid regulatory changes.